{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:32:57Z","timestamp":1791113577528,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1016\/j.ejphar.2008.06.019","type":"journal-article","created":{"date-parts":[[2008,6,11]],"date-time":"2008-06-11T09:33:13Z","timestamp":1213176793000},"page":"264-271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"title":["Spironolactone exhibits direct renoprotective effects and inhibits renal renin\u2013angiotensin\u2013aldosterone system in diabetic rats"],"prefix":"10.1016","volume":"589","author":[{"given":"Masateru","family":"Taira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroe","family":"Toba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikumi","family":"Iga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Serizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Kobara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2008.06.019_bib1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2337\/diab.40.4.405","article-title":"Role of oxidative stress in development of complications in diabetes","volume":"40","author":"Baynes","year":"1991","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2008.06.019_bib2","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.2337\/diab.38.9.1142","article-title":"Mean glomerular volume and rate of development of diabetic nephropathy","volume":"38","author":"Bilous","year":"1989","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2008.06.019_bib3","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM200005043421807","article-title":"Role of transforming growth factor beta in human disease","volume":"342","author":"Blobe","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2008.06.019_bib4","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2008.06.019_bib5","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/j.1523-1755.2004.00913.x","article-title":"Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats","volume":"66","author":"Fujisawa","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2008.06.019_bib6","doi-asserted-by":"crossref","first-page":"39616","DOI":"10.1074\/jbc.M502412200","article-title":"Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney","volume":"280","author":"Gorin","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2008.06.019_bib7","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1210\/en.2006-0944","article-title":"Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus","volume":"147","author":"Guo","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2008.06.019_bib8","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1681\/ASN.2005111196","article-title":"Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats","volume":"17","author":"Han","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2008.06.019_bib9","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s001250051258","article-title":"Oxidative DNA damage in diabetes mellitus: its association with diabetic complications","volume":"42","author":"Hinokio","year":"1999","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2008.06.019_bib10","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2008.06.019_bib11","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2008.06.019_bib12","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2008.06.019_bib13","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1161\/01.RES.71.3.503","article-title":"Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor","volume":"71","author":"Lombes","year":"1992","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2008.06.019_bib14","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1172\/JCI111523","article-title":"Structural\u2013functional relationships in diabetic nephropathy","volume":"74","author":"Mauer","year":"1984","journal-title":"J Clin Invest."},{"key":"10.1016\/j.ejphar.2008.06.019_bib15","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1111\/j.1440-1681.1998.tb02306.x","article-title":"Regulation of aldosterone biosynthesis: the end of the road?","volume":"25","author":"Muller","year":"1998","journal-title":"Clin. Exp. Pharmacol. Physiol. Suppl."},{"key":"10.1016\/j.ejphar.2008.06.019_bib16","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1161\/01.HYP.0000174593.88899.68","article-title":"Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1\/2 in rat renal fibroblasts","volume":"46","author":"Nagai","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2008.06.019_bib17","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1161\/01.HYP.0000118519.66430.22","article-title":"Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone\/salt-induced hypertensive rats","volume":"43","author":"Nishiyama","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2008.06.019_bib18","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2008.06.019_bib19","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2008.06.019_bib20","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/01.HYP.31.1.451","article-title":"Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats","volume":"31","author":"Rocha","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2008.06.019_bib21","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s001250051076","article-title":"Oxidative stress measurement by in vivo electron spin resonance spectroscopy in rats with streptozotocin-induced diabetes","volume":"41","author":"Sano","year":"1998","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2008.06.019_bib22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2008.06.019_bib23","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1042\/cs1020381","article-title":"Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart","volume":"102","author":"Satoh","year":"2002","journal-title":"Clin. Sci. (Lond)"},{"key":"10.1016\/j.ejphar.2008.06.019_bib24","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0002-9343(01)00642-8","article-title":"Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases","volume":"110","author":"Schepkens","year":"2001","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejphar.2008.06.019_bib25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1471-4892(02)00133-9","article-title":"Oxygen radicals in cardiovascular\u2013renal disease","volume":"2","author":"Schnackenberg","year":"2002","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.06.019_bib26","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/ajkd.2001.22069","article-title":"Late escape from the antiproteinuric effect of ace inhibitors in nondiabetic renal disease","volume":"37","author":"Shiigai","year":"2001","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ejphar.2008.06.019_bib27","first-page":"529","article-title":"Aldosterone binding to mineralocorticoid receptors of mononuclear leukocytes in diabetic subjects","volume":"128","author":"Shimada","year":"1993","journal-title":"Acta. Endocrinol. (Copenh)"},{"key":"10.1016\/j.ejphar.2008.06.019_bib28","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1161\/01.HYP.35.5.1078","article-title":"Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats","volume":"35","author":"Sun","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2008.06.019_bib29","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1291\/hypres.24.469","article-title":"Genetic alterations in patients with primary aldosteronism","volume":"24","author":"Takeda","year":"2001","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.ejphar.2008.06.019_bib30","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1681\/ASN.2005020129","article-title":"Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase 1\/2, cyclin D1, and cyclin A","volume":"16","author":"Terada","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2008.06.019_bib31","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejphar.2006.08.036","article-title":"The direct antioxidative and anti-inflammatory effects of peroxisome proliferator-activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozotocin-induced diabetic rat aorta","volume":"549","author":"Toba","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.06.019_bib32","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1161\/01.HYP.0000175814.18550.c0","article-title":"Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor","volume":"46","author":"Xue","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2008.06.019_bib33","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/ki.1991.57","article-title":"The renal tubulointerstitium in diabetes mellitus","volume":"39","author":"Ziyadeh","year":"1991","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2008.06.019_bib34","first-page":"175","article-title":"The diabetic renal tubulointerstitium","volume":"88","author":"Ziyadeh","year":"1995","journal-title":"Curr. Top. Pathol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299908006092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299908006092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T20:02:38Z","timestamp":1728417758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299908006092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":34,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["S0014299908006092"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2008.06.019","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spironolactone exhibits direct renoprotective effects and inhibits renal renin\u2013angiotensin\u2013aldosterone system in diabetic rats","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2008.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}